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AMPA-R Antibody Positive Autoimmune Encephalitis: An Under Recognized
Cause of Acute Mental Status Changes
Joseph Moran DO; George Prousi MD and Stacey Smith MD
Department of Medicine, Lehigh Valley Health Network, Allentown, Pennsylvania
INTRODUCTION

TREATMENT

•	Considered to be a rare culprit of acute mental status changes, autoimmune encephalitis
1
accounts for only 4% of encephalitis cases
•	The presentation of Anti-AMPA-R encephalitis is acute in nature and symptomatology
consists of psychiatric symptoms, behavioral abnormalities and movement disorders
•	Women over the age of 50 with known autoimmune disorders have been most
commonly affected
•	At present, 58% of women and 23% of men who develop this pathologic process are
2
found to have an underlying malignancy

•	Treatment is largely based on the evaluation of case reports and case series with the
majority of approaches revolving around combined therapies.
•	Immunotherapy with either corticosteroids alone or in conjunction with IV
4,5
immunoglobulin or plasma exchange is the mainstay of therapy
•	Second line therapies with rituximab, cyclophosphamide, or combined approach are
4,5
possibilities for those who fail to improve within 4 weeks of immunotherapy
•	It should also be noted that given a significant association with primary tumor
4,5
diagnoses, tumor removal is suggested and has lead to a reduction of antibody levels

CASE PRESENTATION
•	A 60 year old female with a history of rheumatoid arthritis and depression presented
with a one-month history of altered mental status, abnormal behavior and unsteady gait
•	Presenting to an outside hospital, she underwent metabolic, infectious, and
neuroimaging studies that were unremarkable. It was suspected that she had either a
rapidly progressive dementia or a brief psychotic disorder triggered by severe depression
•	Her mental status did not improve over a 15-day hospital course and she was
transferred to our facility. On presentation the patient was not oriented to person place or
time, was writhing, moaning and completely non verbal.
•	Differentials included CJD, Vasculitis, and paraneoplastic / autoimmune encephalitis.
Diagnostic studies returned showing positivity for Anti-AMPA-R antibodies, indicating the
patient had a rare form of autoimmune encephalitis. Extensive work up for underlying
malignancy was negative
•	The patient made significant improvement with plasma exchange therapy,
cyclophosphamide and steroids. Her mental status and behavior returned to baseline and
she was discharged in stable condition

DISCUSSION
•	This case in combination with review of several case series in literature suggests that
the detection of AMPA-R antibodies be considered in patients, particularly women,
older than 50 years who present not only with limbic encephalitis but also with rapidly
1
progressive abnormal behaviors resembling acute psychosis
•	This patient’s history of a previously diagnosed autoimmune disease should also have
prompted consideration. Literature suggests that up to 50% of patients diagnosed
with AMPA-R Ab positive autoimmune encephalitis had history of another systemic
2
autoimmune disease
•	Early detection is crucial due to the high association AMPA-R Ab positive autoimmune
encephalitis has with underlying malignancy. An underlying tumor was discovered in
2
64% of patients in a case series of 22 patients
•	Patients without malignancy tend to respond very well to immunotherapy; however,
close follow up is indicated due to a relapse rate of up to 50% and diagnosis of a
2,3
primary tumor has occurred during relapses
•	Overall, the prognosis for this patient is very favorable with literature showing a 100%
5 year survival in patients without underlying malignancy compared with a 50% 5 year
2
survival in those with underlying malignancy
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